Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Catalent Pharma Solutions LLC currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners and 3 distinct art units, indicating a lack of concentration in any single examination group. This distribution suggests that the company's current prosecution efforts are spread across different technical specialties within the broader pharmaceutical field. Practitioners should note that no single art unit or examiner holds a majority of the pending workload.
The busiest examiner for this portfolio is CHI, AMANDA LYNN, who is responsible for 1 pending office action. Given that the total number of pending office actions is 3 and the number of distinct examiners is also 3, each examiner is currently handling a single case. This one-to-one ratio between actions and examiners, as well as actions and art units, reflects a fragmented prosecution landscape for the 3 pending matters. The presence of 3 distinct art units confirms that the portfolio is not clustered in a specific sub-specialty at this time.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHI, AMANDA LYNN | 1 | — | — |
| LU, CHENG | 1 | 53.8% | +64.6% |
| KONOPKA, CATHERINE ANNE | 1 | 57.5% | +66.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18007568 | NUCLEIC ACID CONSTRUCTS FOR PROTEIN MANUFACTURE | KONOPKA, CATHERINE ANNE | 30d overdue |
| 18849392 | LIQUID FORMULATIONS OF IVERMECTIN COMPOSITIONS AND USE IN GELATIN DOSAGE FORMS | CHI, AMANDA LYNN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18007568 | NUCLEIC ACID CONSTRUCTS FOR PROTEIN MANUFACTURE | KONOPKA, CATHERINE ANNE | 30d overdue |
| 18532395 | MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND USE THEREOF | LU, CHENG | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1642 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18849392 | LIQUID FORMULATIONS OF IVERMECTIN COMPOSITIONS AND USE IN GELATIN DOSAGE FORMS | CHI, AMANDA LYNN | 1613 | §103§112 | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18532395 | MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND USE THEREOF | LU, CHENG | 1642 | §103 | Non-Final OA | — | Pending | Dec 07, 2023 |
| 18007568 | NUCLEIC ACID CONSTRUCTS FOR PROTEIN MANUFACTURE | KONOPKA, CATHERINE ANNE | 1635 | §101§103§112Other | Final Rejection | 30d overdue | Pending | Dec 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCatalent Pharma Solutions LLC has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Amanda Lynn Chi has the most, with 1 of Catalent Pharma Solutions LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
